All News

Article

TNR Recap: What Patients Say about PsA

Jack Cush, MD Apr 06, 2022

Watch this outstanding and informative Tuesday Nite Rheumatology, held on April 5th, 2022 which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.

PsA Panelists included:

- Tena Brown

- Christine Lindsay

- Ashley Krivohlavek

Article

Dactylitis Indicates a Severe PsA Phenotype

Jack Cush, MD Apr 05, 2022

A recent study analyzed the impact of dactylitis in disease-modifying antirheumatic drug (DMARD)-naive early psoriatic arthritis (PsA) and found that DMARD-naive PsA patients with dactylitis (dactylitic PsA) have a greater burden of disease than those without dactylitis.

Australian study from 2 #PSA clinics PsA clinics compared RAPID3 score to MDA, very low disease activity (VLDA) & DAPSA. 93 pts showed RAPID3 correlated w/ ROC AUC for VLDA (0.94) and DAPSA (0.96) https://t.co/x9G8wTpeS6 #PsAlways https://t.co/WuseKMoiJj

https://bit.ly/3IZKYUs

QD Clinic - PsA Lessons from the Clinic Does the Moll & Wright Classification of PsA hold up? QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022 https://t.co/zskcsZ4kkW https://t.co/QZOb09wGyp

https://bit.ly/35FLRnv

Czech registry compared drug survival csDMARDs vs TNFi monotherapy. Drug retention higher w/ combo (47 vs 23 mos; p < 0.001) than TNFi monotherapy. 5 yr survival was better 45% vs 26%; Combo w/ MTX > other csDMARDs (p = 0.003). https://t.co/pjbXwEQ53K https://t.co/nZj64Wk3Pt

https://bit.ly/35GT0nI

520 RA pts were screened with FibroScan (liver fibrosis)- F3 or F4 liver fibrosis seen 13.3% of controls vs 12.7% arthritis pts. MTX was not significantly correlated w/ higher FS scores. Liver stiffness was correlated w/ BMI, waist, male , age. https://t.co/iKvsITCs33 https://t.co/Dqos1MT431

https://bit.ly/3J7Am61

Steroids associated with adverse events during pregnancy ⁦@UmaMahadevanIBD⁩ ⁦@MayoClinicGIHep⁩ https://t.co/VR5CZUH1S7

Avacopan efficacy in renal failure in AAV. Appears to have benefit in renal disease that is more marked the more severe the disease is #Vasculitis22 https://t.co/3zsxjTLj62

The striking and most welcome streak of US Covid hospitalizations going down every single day since mid-January continues, now well below the prior pandemic nadir, and even after facing BA.2 variant dominance in parts of the country weeks ago 👍 https://t.co/WUZUCb2TOK

#ClinicalPearl Overall #azathioprine wins for maintenance of remission in ANCA associated #vasculitis with equal remission in MPO+ but less with AZA inPR3+. So use AZA but if not tolerated sometimes MMF is ok. Otherwise consider #Leflunomide or if bad organ involvement #Rituximab https://t.co/efi8cKQ36B

Richard Conway on Twitter: "Subgroup analysis of IMPROVE study looking at …

ALEVIATE - small study of Alemtuzumab (anti-CD52) in 23 refractory ANCA-Assoc vasculitis or Behcets— 16/23 (70%) had either complete (6/23, 26%) or partial (10/23, 44%) response at 6 months. 10 SAE in 7 (30%) pts https://t.co/EciG0Mkn4i https://t.co/7UmDA4NxqV

https://bit.ly/3x2lBik

RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/is2O1dewcr

Network metaanalysis studied 46 RCTs biologics in #PsA. Some TNFi's numerically (not signif) better vsn interleukin inhib for ACR resps, but worse on PASI resps (IL-23, IL-17i had better PASI responses); No diff in enthesitis & dactylitis resps https://t.co/AvnoLRVi6C #PsAlways https://t.co/BSl9hVbIx6

https://bit.ly/3DJpOZJ

Metanlysis of psychological interventions for chronic low back pain (97 RCTs, 13,136 pts) finds that Only behavioural therapy delivered w/ physiotherapy care (mainly structured exercise) reduced pain intensity up (high quality evidence) https://t.co/wHHvj0vey9 https://t.co/PBwyitTZxK

https://bit.ly/35AHBWm

211 pts presenting w/ hot swollen joint to the ER; 28 w/ septic arthritis; pseudogout 32; gout 50; & others: 101. Predictors of Septic Arthritis: RA (OR 3.4); skin infx (OR 3.3); liver Dz (OR 9.9); knee involv (OR 3.5); immunosuppressive use (OR 3.5) https://t.co/uASovNVOWb https://t.co/Fq3obVDavm

https://bit.ly/3DAf3c2

TONIGHT! Join us for Tuesday Night Rheumatology on April 5 at 7pm ET. Register today! https://t.co/jewQ9RE88n https://t.co/EfFiztByub

https://bit.ly/3u8InDB

15 RTX patients with no response to 2 doses of SARS-CoV-2 vaccine received a booster. Despite persistent B-cell depletion 7/15 had a response to booster vaccine #Vasculitis22 https://t.co/y8y8Bjnqtp

The BA.2 variant is now dominant in every region of the United States and accounts for 72% overall for new Covid cases https://t.co/jjl2AnwOWX @CDCgov https://t.co/ot1GNez51W

CDC COVID Data Tracker

Your Psoriatic Questions from RNL 2022 Dr. Jack Cush fields Rheumatologists questions from RNL 2022 QD Clinic is sponsored by RheumNow's PsA All the Way Campaign in April 2022. https://t.co/DlW5KA3mEo https://t.co/wtTlYJs89l

https://bit.ly/3j6bQHG

RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/PlUfbo8FNd

Topics

All News

TNR Recap: What Patients Say about PsA

Dactylitis Indicates a Severe PsA Phenotype

Do you get our email newsletter?